Gelesis100 Reduces Insulin-Resistance in GLOW Obesity Trial
Data from the pivotal GLOW trial presented at the Endocrine Society's annual meeting show that Gelesis' Gelesis100 non-systemic, superabsorbent hydrogel significantly reduces insulin-resistance compared to placebo in overweight and obese patients.
